In support of this hypothesis, Won et al. suggested that β-catenin plays a key role in tamoxifen-resistant BC and proposed the inhibition of β-catenin as a potential strategy to overcome tamoxifen resistance in ER+ BC [69]. Here, ESR1 is linked to breast cancer.